Viewing data from:

ORPHENADRINE CITRATE

ANDA

ORPHENADRINE CITRATE | A040463 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part B Spending

CMS physician-administered drug spending for Orphenadrine Citrate (2023)

Total Spending

$47K

Total Claims

6,482

Beneficiaries

4,518

ASP Price

—

HCPCS: J2360 — Injection, orphenadrine citrate, up to 60 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain4 active DMFs3 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

W R GRACE AND CO -CONNORPHENADRINE CITRATE USP

DMF 57221985

PROCOS SPAORPHENADRINE CITRATE

DMF 149712000

R L FINE CHEM PVT LTDORPHENADRINE CITRATE

DMF 339012019

R L FINE CHEM PVT LTDORPHENADRINE CITRATE

DMF 384562023

ORGAMOL SAInactiveORPHENADRINE CITRATE AND ORPHENADRINE HCL.

DMF 48111983

3M PHARMACEUTICALSInactiveORPHENADRINE CITRATE

DMF 71081987

IROPHARM LTDInactiveORPHENADRINE CITRATE

DMF 78371988

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 30MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Mar 4, 2003

No patent or exclusivity listings for this strength.